TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Australia’s Recce, Etana team up to develop synthetic antibiotics in Indonesia
The private sector agreement aims to develop a new class of synthetic antibiotics to address the growing issue of drug-resistant superbugs, which can cause previously treatable infectious diseases to become deadly.
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
Health Minister Budi Gunadi Sadikin (center) speaks with companies involved in the development of synthetic antibiotics, a new technology that aims to address increased antibiotic resistance, in Jakarta in January 2024. (Courtesy of Recce Pharmaceuticals/-)
A
ustralia’s Recce Pharmaceuticals and Jakarta-based drug manufacturer Etana Biotechnologies Indonesia have started preparations for clinical trials to implement an agreement on clinical research for, and the manufacturing of, a new class of synthetic antibiotics for a range of diseases.
Signed in February, the agreement aims to develop the new class of antibiotics to address the growing issue of drug-resistant superbugs, which can cause previously treatable infectious diseases to become deadly.
Preclinical studies show that the synthetic anti-infective RECCE-327 has the potential to be effective in treating serious and potentially life-threatening infections caused by gram-positive and negative bacteria, including ESKAPE, an acronym for six highly virulent and drug-resistant pathogens, even in their superbug forms.
Recce Pharmaceuticals CEO James Graham said antimicrobial resistance was a global problem that affected all countries.
“But certainly in Indonesia, there are thousands of deaths each year, and these happen in preventable circumstances,” Graham told The Jakarta Post in an interview on Tuesday.
He insisted that the need for new antibiotics had never been greater.
“The groundbreaking research that is happening in Indonesia, in major unmet medical needs of large patient populations, means that Indonesian people will have this new class of antibiotics and be the first to access this most advanced new class of antibiotics,” Graham said.
